The price of NEO is predicted to go up 3.15%, based on the high correlation periods with DHR. The similarity of these two price pattern on the periods is 96.14%.
NEO
DHR
Up: 3.15%Similarity: 96.14%
NEO Revenue Forecast
NEO EPS Forecast
NEO FAQs
What is bull’s view on NEO?
NeoGenomics (NEO) has a bullish outlook with analysts maintaining strong buy ratings and an average price target of $19, representing a 29% upside from its current price of $14.78. The optimism stems from its strategic partnership with Adaptive Biotechnologies and positive earnings estimate revisions, signaling potential growth in its cancer diagnostics business. However, recent leadership changes may introduce short-term volatility.
What is bear's view on NEO?
NeoGenomics (NEO) currently trades at $14.21, with analysts lowering price targets to $18-$19 due to leadership concerns after the CEO's unexpected resignation. Despite this, the stock shows potential upside (up to 48%) driven by strategic partnerships and improving earnings estimates. However, uncertainty around management stability remains a bearish factor.
What is NEO revenue forecast for next quarter?
The market consensus for NEO's revenue in the upcoming quarter is projected to be approximately $172.625M USD.
What is NEO eps forecast for next quarter?
The market consensus for NEO's eps in the upcoming quarter is projected to be approximately $0.018 USD.
BofA analyst Derik de Bruin raised the firm's price target on NeoGenomics to $19 from $18 and keeps a Neutral rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech customers reined in spending after overspending during the pandemic and China remained "very subdued," the analyst tells investors. Entering 2025, "the setup is almost identical, so there is a healthy dose of skepticism among investors who have been burned over the past year," says the firm, which adds that thinks "there are finally some encouraging signs on the horizon." In conjunction with its year ahead preview for the group, the firm adjusted a number of price targets.